Granzyme B

Ongoing clinical trials and approved products targeting Granzyme B, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials
7ongoing imaging trials
0approved products

Target note

Full name
Granzyme B
Nature
Serine protease released by activated cytotoxic T lymphocytes and NK cells.
Normal expression
—
Value
Measuring cytotoxic activity within the tumor to predict the response to immunotherapy.
Approaches
Peptides labeled with ⁶⁸Ga (GZP, grazytracer).
Indications explored
Tumors under immunotherapy (research).
Points of caution
Early stage.

Ongoing imaging trials · 7Open in the radar →

TrialPhaseStatusSponsorCountries
Granzyme B tracerNCT05888532 · Prostate – mCRPCPhase 2RecruitingRahul Aggarwal1
Granzyme B tracerNCT07724535 · LymphomaPhase 2RecruitingPeking University Cancer Hospital & Institute1
Granzyme B tracerNCT07774650 · OtherPhase 1RecruitingRatio Therapeutics, Inc.1
Granzyme B tracerNCT06522932 · LymphomaPhase 1RecruitingMichael Randall1
Granzyme B tracerNCT07481136 · OtherPhase 1Not yet recruitingJavid Moslehi, MD1
Granzyme B tracerNCT07022080 · Inflammatory diseasesNo phaseNot yet recruitingXijing Hospital1
Granzyme B tracerNCT07657494 · LymphomaNo phaseRecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences1

Cite this page

Granzyme B. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/granzyme-b/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.